Lycopodium Targets Major FY27 Growth on Expanding Global Pipeline

Lycopodium posts solid FY26 results but future growth relies on long-dated, unproven pipeline.

What the company is saying

Lycopodium presents its FY26 results as meeting guidance, highlighting $377.5 million in revenue and $40.2 million NPAT. The announcement emphasizes an expanding global footprint, a $661 million contract backlog, and a strong cash position of $106.2 million. Management frames FY27 as a breakout year, guiding to $540–580 million revenue and $54–58 million NPAT, with the midpoint implying 50% revenue and 40% NPAT growth. The company underscores a robust pipeline—more than 90 studies, over 50 projects, and $11.4 billion in capital value—alongside a new $37 million EPCM contract in Bolivia, though this is subject to a final investment decision. Dividend increases and a zero lost time injury frequency rate are used to reinforce operational strength. The tone is upbeat and forward-looking, but operational details for many claims are either generalized or lack supporting numbers.

What the data suggests

FY26 revenue rose 11% to $377.5 million, but EBITDA fell 13% to $59.5 million and NPAT dropped 5% to $40.2 million, compressing the NPAT margin to 10.6%. The company’s cash balance of $106.2 million and equity of $170.7 million (up 13% year-on-year) signal balance sheet strength, while dividends increased 69% to 59 cents per share, with a 60% payout ratio. Contracted backlog at June 30 was $661 million, but the largest new contract—a $37 million EPCM award in Bolivia—is not yet unconditional. FY27 guidance targets $540–580 million revenue and $54–58 million NPAT, but these are projections, not realised outcomes. The Americas contributed about $40 million (11%) of FY26 revenue, and the company claims a $1.4 billion revenue opportunity pipeline, though no conversion rate or binding status is disclosed. Operational claims such as project completions, headcount growth, and pipeline size are not fully substantiated by the data provided.

Analysis

The announcement presents a positive tone, highlighting revenue and NPAT delivery, contract wins, and a strong balance sheet. However, while FY26 results are supported by disclosed numbers, the most ambitious claims—such as FY27 guidance (50% revenue and 40% NPAT growth), a $1.4bn pipeline, and a $37m EPCM contract for a plant not due for completion until 2030—are forward-looking and not yet realised. The pipeline and project value figures are large but lack detail or binding status, and the new Bolivia contract is still subject to a final investment decision, making its contribution uncertain and long-dated. Although profitability metrics are disclosed for FY26, the margin compression (EBITDA and NPAT both down) is downplayed relative to the upbeat narrative. The capital intensity is high, with billions in managed and studied capital, but immediate earnings impact from these projects is not demonstrated. Overall, the narrative inflates the signal by emphasizing future potential and pipeline size over current, realised profitability.

Risk flags

• ●Profitability is under pressure despite revenue growth, with EBITDA down 13% and NPAT down 5% in FY26. This margin compression could persist if cost inflation or project mix worsens, directly impacting future earnings.
• ●A significant portion of the growth narrative relies on forward-looking pipeline figures—$1.4 billion in potential revenue and $11.4 billion in studies—without disclosure of conversion rates or binding contract status. This creates uncertainty about how much of the pipeline will actually translate into revenue.
• ●The $37 million EPCM contract in Bolivia is subject to a final investment decision and will not contribute meaningfully until 2030 at the earliest. Delays or cancellation would materially reduce the expected long-term uplift.
• ●FY27 guidance for 50% revenue and 40% NPAT growth is ambitious and not yet supported by secured contracts. Missing this guidance would undermine management credibility and investor confidence.
• ●Operational claims such as project completions, headcount growth, and regional expansion are not fully substantiated by numerical evidence, raising questions about the reliability of the broader growth story.

Bottom line

Lycopodium’s FY26 results confirm solid revenue growth and a strong balance sheet, but profitability is slipping as margins compress. The company’s bullish FY27 guidance and large project pipeline are not yet backed by binding contracts or detailed conversion data, making future growth projections speculative. The new Bolivia contract is long-dated and contingent on a final investment decision, so its impact is neither immediate nor certain. Dividend increases and safety performance are positives, but the operational expansion narrative lacks numerical support. For investors, the key issue is whether pipeline projects can be converted into realised earnings without further margin erosion. The most important takeaway: current financial strength is real, but the next leg of growth remains unproven and exposed to execution and pipeline risks.

Announcement summary

(ASX: LYL) Lycopodium has delivered FY26 revenue of $377.5 million and $40.2m NPAT, meeting guidance while expanding its global project footprint and secured workload. Revenue increased 11% from FY25, although EBITDA fell 13% to $59.5m and NPAT eased 5% as the NPAT margin moderated to 10.6%. The engineering and project delivery group has guided to FY27 revenue of $540m to $580m and NPAT of $54m to $58m, with the midpoint representing about 50% revenue growth and 40% NPAT growth. Committed contracts stood at $661m at 30 June, while a strong balance sheet with $106.2m cash supported a fully franked final dividend of 37 cents per share, taking full-year dividends to 59 cents. Lycopodium finished FY26 with equity of about $170.7m, up 13% year-on-year, minimal debt and net tangible assets of $3.92 per share. The business managed about nine million controlled service hours across its operations during the year and recorded a lost time injury frequency rate of zero. That regional push was reinforced this week by an approximately $37m engineering, procurement and construction management (EPCM) contract from Minera San Cristóbal S.A. for a new silver oxide plant at the San Cristóbal mine in Bolivia, subject to a final investment decision.

Disagree with this article?